Related Experiment Video
Updated: Jun 26, 2026
Detection of Functional Matrix Metalloproteinases by Zymography
Published on: November 8, 2010
Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis
Y Benesová1, A Vasku, H Novotná
1Department of Neurology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. beneivo@seznam.cz
Background:
Matrix metalloproteinases are notable contributors to neuroinflammation and blood-brain barrier disruption in multiple sclerosis (MS).
Objective:
The goal of this study was to determine the serum levels of matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-2 (MMP-2), and their tissue inhibitors (TIMP-1) and (TIMP-2), and to investigate their possible relations to type, disability, and severity of MS.
Materials And Methods:
Eighty-seven patients with definite MS according to the McDonald criteria and 50 healthy controls were enrolled in the study. Their clinical status was evaluated with the Expanded Disability Status Scale. Serum levels were analyzed by enzyme-linked immunoassay.
Results:
A significant elevation in MMP-9 serum levels and in the MMP-9/TIMP-1 ratio was found in the whole MS group (P<0.001), in the relapsing-remitting MS (RRMS) (P<0.001), and secondary-progressive MS (SPMS) (P<0.001) groups when compared with the controls. A significant elevation in MMP-2 serum levels and in the MMP-2/TIMP-2 ratio was observed in the primary progressive (P<0.001) and the SPMS (P<0.002) groups when compared with the RRMS group, and this increase was also associated with the disability (P<0.001) and severity (P<0.05) of the disease.
Conclusion:
We confirmed that metalloproteinases are useful biological markers in MS, providing information about the clinical type, disability, and severity of the disease.
Insights
Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are elevated in multiple sclerosis (MS) patients. These biomarkers correlate with MS type, disability, and disease severity, aiding in clinical assessment.
Area of Science:
- Neuroimmunology
- Biomarker Discovery
Background:
- Matrix metalloproteinases (MMPs) contribute to neuroinflammation and blood-brain barrier disruption in multiple sclerosis (MS).
- Understanding MMPs' role is crucial for MS pathogenesis and treatment.
Purpose of the Study:
- To quantify serum levels of MMP-9, MMP-2, TIMP-1, and TIMP-2 in MS patients.
- To explore correlations between these biomarkers and MS clinical characteristics (type, disability, severity).
Main Methods:
- Enzyme-linked immunoassay used to analyze serum samples.
- Study included 87 MS patients and 50 healthy controls.
- Expanded Disability Status Scale assessed clinical status.
Main Results:
- Elevated MMP-9 and MMP-9/TIMP-1 ratio observed in the overall MS group, including relapsing-remitting MS (RRMS) and secondary-progressive MS (SPMS) subtypes.
- Increased MMP-2 and MMP-2/TIMP-2 ratio found in primary progressive MS (PPMS) and SPMS compared to RRMS.
- MMP-2 elevation correlated significantly with MS disability and disease severity.
Conclusions:
- Metalloproteinases serve as valuable biomarkers in MS.
- These biomarkers provide insights into MS clinical subtypes, disability progression, and disease severity.
